Tracon Pharmaceuticals Stock Beta
TRACON Pharmaceuticals fundamentals help investors to digest information that contributes to TRACON Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of TRACON OTC Stock. The fundamental analysis module provides a way to measure TRACON Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to TRACON Pharmaceuticals otc stock.
TRACON |
TRACON Pharmaceuticals OTC Stock Beta Analysis
TRACON Pharmaceuticals' Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Current TRACON Pharmaceuticals Beta | 1.24 |
Most of TRACON Pharmaceuticals' fundamental indicators, such as Beta, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, TRACON Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
CompetitionIn accordance with the recently published financial statements, TRACON Pharmaceuticals has a Beta of 1.243. This is 44.53% higher than that of the Biotechnology sector and 10.58% lower than that of the Health Care industry. The beta for all United States stocks is notably lower than that of the firm.
TRACON Beta Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses TRACON Pharmaceuticals' direct or indirect competition against its Beta to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of TRACON Pharmaceuticals could also be used in its relative valuation, which is a method of valuing TRACON Pharmaceuticals by comparing valuation metrics of similar companies.TRACON Pharmaceuticals is currently under evaluation in beta category among its peers.
As the market goes up, the company is expected to outperform it. However, if the market returns are negative, TRACON Pharmaceuticals will likely underperform.
TRACON Fundamentals
| Return On Equity | -12.77 | ||||
| Return On Asset | -0.2 | ||||
| Profit Margin | 0.14 % | ||||
| Operating Margin | (32.12) % | ||||
| Current Valuation | (2.64 M) | ||||
| Shares Outstanding | 2.68 M | ||||
| Shares Owned By Insiders | 2.20 % | ||||
| Shares Owned By Institutions | 11.42 % | ||||
| Number Of Shares Shorted | 166.13 K | ||||
| Price To Earning | (1.51) X | ||||
| Price To Book | 11.83 X | ||||
| Price To Sales | 0.45 X | ||||
| Revenue | 12.04 M | ||||
| Gross Profit | (13.89 M) | ||||
| EBITDA | (6.88 M) | ||||
| Net Income | (3.59 M) | ||||
| Cash And Equivalents | 13.58 M | ||||
| Cash Per Share | 0.63 X | ||||
| Total Debt | 968 K | ||||
| Debt To Equity | 0.35 % | ||||
| Current Ratio | 1.17 X | ||||
| Book Value Per Share | (0.66) X | ||||
| Cash Flow From Operations | 3.68 M | ||||
| Short Ratio | 0.95 X | ||||
| Earnings Per Share | 106.40 X | ||||
| Target Price | 30.5 | ||||
| Number Of Employees | 17 | ||||
| Beta | 1.24 | ||||
| Market Capitalization | 3.83 M | ||||
| Total Asset | 10.11 M | ||||
| Retained Earnings | (240.5 M) | ||||
| Working Capital | (1.09 M) | ||||
| Current Asset | 53.31 M | ||||
| Current Liabilities | 14.18 M | ||||
| Net Asset | 10.11 M |
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in persons. You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Other Consideration for investing in TRACON OTC Stock
If you are still planning to invest in TRACON Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the TRACON Pharmaceuticals' history and understand the potential risks before investing.
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Fundamental Analysis View fundamental data based on most recent published financial statements |